Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo

Company states the realisation of generic competition is neither certain nor imminent

15-Nov-2007

Orion Corporation has filed a patent infringement lawsuit in the United States to enforce its formulation patent, U.S. Patent No. 6,500,867, against Sun Pharmaceutical Industries Inc. and Sun Pharmaceutical Industries Limited, who seek to market generic versions of Stalevo® tablets (25/100/200 and 37.5/150/200 mg strengths of carbidopa/levodopa/entacapone) in the United States. Stalevo is an enhanced levodopa treatment originated by Orion Corporation and marketed in the United States by its exclusive licensee, Novartis, for the treatment of Parkinson's disease. Orion Corporation and Novartis will vigorously defend the intellectual property rights covering Stalevo.

Other news from the department politics & laws

Most read news

More news from our other portals

Discover the latest developments in battery technology!